For the last few years, Evaluate Ltd., a life science market intelligence firm,
has been assembling their annual Evaluatepharma® orphan Drug Report,
based on coverage of over 5,000 of the world’s leading pharmaceutical and
biotech companies. The latest results show that the sector continues to grow,
and at a much faster rate—almost 12%—than the industry as a whole, which
is at 5.9%.
Orphan Drugs Set to Outpace Industry